Now Available ONTRUZANT®

ONTRUZANT® is a HER2/neu receptor antagonist indicated for:

• The treatment of HER2-overexpressing breast cancer.
• The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-overexpressing breast cancer.

Please see the Full Prescribing Information.